BioSpace News Archive

Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced its plans to release financial results for its third quarter ended September 30, 2022 after the close of trading on November 2, 2022.

Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose –  unleashing tools to accelerate breakthroughs in human health – today announced that it will report third quarter 2022 financial results on Tuesday, November 8, 2022, after the close of the market.

Agenus today announced the Company will release its second quarter 2022 financial results before the market opens on Tuesday, November 8, 2022.

AcelRx Pharmaceuticals, Inc. today announced that an abstract entitled, “Evolution Of Opioid Analgesia On The Battlefield For Moderate-to-Severe Acute Pain” (abstract # A4123) was presented by lead author, Sharon Kim, M.S., at the ANESTHESIOLOGY® 2022 annual meeting, held October 21-25, 2022 in New Orleans, LA.

Veracyte, Inc . (Nasdaq: VCYT) announced new data demonstrating that a genomic signature derived from the company’s Decipher GRID database could help determine which men experiencing prostate cancer progression following radical prostatectomy (RP).

HeartBeam, Inc will hold a conference call on Thursday November 10, 2022 at 4:30 p.m. Eastern time to discuss its results for the third quarter ended September 30, 2022, and will be reviewing recent announcements, ongoing initiatives, and key 2022 and anticipated 2023 milestones.

Epic Bio today announced its participation at the 6th International Conference on Epigenetics and Bioengineering, held in Houston, Texas, taking place October 27 – 29, 2022.

Neogen Corporation (NASDAQ: NEOG) announced today that the Megazyme Rapid Integrated Total Dietary Fiber (RINTDF) method has been accepted by the Association of Official Analytical Chemists (“AOAC International”).

The global DNases, ligases, and RNA polymerases market size was estimated at USD 611.97 million in 2021 and it is expected to surpass around USD 1.4 billion by 2030, poised to grow at a CAGR of 9.63% from 2022 to 2030.

According to Vision Research Reports, the global immunofluorescence assay market size is expected to surpass around USD 4.61 billion by 2030, poised to grow at a CAGR of 6.8% from 2022 to 2030.